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A B S T R A C T
Orthobunyaviruses include several recently emerging viruses of significant medical and veterinary importance.
There is currently very limited understanding on what determines the host species range of these pathogens. In
this study we discovered that BST-2/tetherin restricts orthobunyavirus replication in a host-specific manner.
We show that viruses with human tropism (Oropouche virus and La Crosse virus) are restricted by sheep BST-2
but not by the human orthologue, while viruses with ruminant tropism (Schmallenberg virus and others) are
restricted by human BST-2 but not by the sheep orthologue. We also show that BST-2 blocks orthobunyaviruses
replication by reducing the amount of envelope glycoprotein into viral particles egressing from infected cells.
This is the first study identifying a restriction factor that correlates with species susceptibility to orthobunya-
virus infection. This work provides insight to help us dissect the adaptive changes that bunyaviruses require to
cross the species barrier and emerge into new species.
1. Introduction
The increase in travel and commercial trade over the last two
decades, in addition to climate and ecological changes, have
facilitated the emergence of a variety of pathogenic viruses
(Karesh et al., 2012). Several recently emerging viruses belong to
the Bunyavirales order (classified until recently simply as the
Bunyaviridae family), a large group of enveloped RNA viruses that
comprise more than 350 named virus isolates divided among nine
virus families and thirteen genera, including some which cause
important diseases in humans, livestock and crops (Adams et al.,
2017; Ergonul, 2012; McMullan et al., 2012; Yu et al., 2011).
Within the Peribunyaviridae, the genus Orthobunyavirus includes
more than 170 named viruses some of which are of medical and
veterinary importance (Elliott, 2014). The orthobunyavirus gen-
ome comprises three segments referred to as large (L), medium (M)
and small (S). The large segment encodes for the viral polymerase.
The M segment encodes for the viral glycoproteins Gn-NSm-Gc that
are synthesized as a poplyprotein precursor that is later proteoli-
tically cleaved. The S segment encodes for the viral nucleocapsid
and the non-structural protein NSs in an overlapping reading frame
(Eifan et al., 2013).
Orthobunyaviruses like Oropouche virus (OROV), La Crosse
(LACV) virus and Ngari virus can be the cause of febrile illnesses,
encephalitis or hemorrhagic fevers in humans (Bowen et al., 2001;
Pinheiro et al., 1981). On the other hand, orthobunyaviruses such as
Akabane virus (AKAV), Sathuperi virus (SATV) and the recently
emerged Schmallenberg virus (SBV) cause abortions and congenital
malformations in ruminants (Calisher, 1996; Kurogi et al., 1975),
while Cache Valley virus (CVV) causes disease both in ruminants and
humans.
Important public health considerations need to be made when a
new orthobunyavirus emerges. For example, SBV emerged in
Germany in the summer of 2011 (Hoffmann et al., 2012) and spread
very rapidly throughout Europe. On the bases of epidemiological
data and the similarity of SBV to other orthobunyaviruses infecting
ruminants, the risk of transmission of SBV to humans was con-
sidered low. Indeed, subsequent studies showed that no antibodies
against this virus were detected in individuals in contact with
infected animals (Ducomble et al., 2012; Reusken et al., 2012).
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Hence, with some notable exceptions (i.e. CVV), it appears that
many of the medically or veterinary relevant orthobunyaviruses have
a fairly strict host range as they cause disease either in humans or
ruminants.
Virus tropism for a particular animal species is determined by
many factors including, in some cases, innate immune responses.
Vertebrates have evolved a variety of mechanisms to counteract
exposure to pathogens. A key innate immune mechanism to fight
virus infection is the type I interferon (IFN) and pro-inflammatory
responses. Secretion of IFN by infected cells leads to autocrine and
paracrine signaling resulting in the activation of hundreds of IFN-
stimulated genes (ISGs) some of which have a direct or indirect
antiviral effect (Nan et al., 2014; Yan and Chen, 2012). In turn,
viruses have evolved mechanisms to counteract host restriction
factors. Available evidence, mainly provided by studies on primate
lentiviruses (Wain et al., 2007), suggests that viruses that have
successfully established themselves in a given species are able to
counteract, at least partially, the innate immune response of the
host (Hrecka et al., 2011; Stremlau et al., 2004, 2006). Conversely,
the same viruses cannot overcome the innate responses of non-
susceptible species. Hence, sequence differences within ISGs
orthologues could provide at least partial susceptibility or resis-
tance to a given virus infection.
As most emerging human viruses are predicted to be zoonotic in
origin (Mandl et al., 2014), it is important to assess the zoonotic
potential of any newly discovered veterinary pathogen.
Understanding the molecular mechanisms determining virus host
range is key to gain insight into the rules that govern viral
emergence. Cross-species transmission requires overcoming host-
specific barriers that can be present at each stage of the viral
replication cycle and can be specific for different animal species.
Our understanding of the effect of host ISGs on bunyavirus host
range, as well as the molecular adaptations required to overcome
host genetic barriers is limited. In vitro, orthobunyaviruses grow
extremely efficiently in a variety of cell lines derived from different
species. Hence, the host range of these viruses does not seem to be
due to species-specific cellular receptors or other factors absolutely
required for virus replication. An ISG with a broad inhibitory
activity against enveloped viruses is BST-2 (also known as tetherin,
CD317, HM1.24) (Neil et al., 2008; Sauter, 2014; Van Damme
et al., 2008). BST-2 is a type II membrane protein with an unusual
topology consisting of a coiled-coiled ectodomain bound to the cell
membrane by an N-terminal transmembrane domain and a C-
terminal GPI anchor. The BST2 gene is duplicated in ruminants:
sheep and cows possess two BST2 paralogs, BST2A and BST2B,
both with antiviral properties although probably displaying differ-
ent mechanisms of action (Murphy et al., 2014; Takeda et al.,
2012). Ovine BST2B (oBST2B) displays particular features: it lacks
predicted glycosylation sites and a carboxy terminal GPI anchor,
resulting in a protein that is retained within the Golgi apparatus
(Murphy et al., 2014). In this study, we investigated the role of
BST-2 in determining orthobunyavirus host range. We found that
BST-2 restricts orthobunyaviruses replication in a species-specific
manner and thus likely contributes to determine the host range of
this important group of viruses.
2. MATERIALS AND METHODS
2.1. Cell lines
HEK-293T and BSR cells were grown in Dulbecco's modified
Eagle's medium (DMEM). BSR-T7/5 cells (provided by Karl
Conzelmann) were grown in Glasgow modified Eagle's medium.
Sheep choroid plexus cells (CPT-Tert) (Arnaud et al., 2010) were
grown in Iscove's modified Dulbecco's medium. Human primary
dermal fibroblasts were obtained from ATCC and cultured in fibroblast
growth media 2 (Promo Cell). All cell lines were supplemented with
10% fetal bovine serum (FBS) and penicillin and streptomycin (p/s)
and cultured at 37 °C in a 5% CO2 and 95% humidified atmosphere.
2.2. Antibodies
Antisera used in this study included a rabbit polyclonal antiserum
against the SBV N protein (Proteintech) (Varela et al., 2013), a
polyclonal antibody against SBV Gc protein (Gensript), a monoclonal
antibody against Gc (Wernike et al., 2017) and a polyclonal antibody
against whole OROV. Polyclonal antibody against the HA tag was
obtained from Abcam. HIV p24 was obtained through the NIH AIDS
Reagent Program (HIV-1 p24 Hybridoma (183-H12-5C)) (Chesebro
et al., 1992). Antibody against γ-tubulin was obtained from Sigma.
Fluorescent secondary antibody included AlexaFlour 488 or 594 goat
anti rabbit (Life technologies).
2.3. Viruses
Wild type SBV was obtained by reverse genetics as previously
described (Varela et al., 2013). AKAV was rescued by reverse genetics
using the plasmids described below. The origin of SATV was described
previously (Watret et al., 1985). OROV was supplied by Christian
Drosten (Institute of Virology, Bonn Medical Centre, Bonn, Germany).
LACV was supplied by Friedman Weber. The 6V633 strain of CVV was
used.
2.4. Plasmids
Plasmids expressing the HA tagged version of human Bst-2
(pCR3.1-hBST2-HA), ovine Bst2-A and -B (pCIoBST2A-HA and
pCIoBST2B-HA), an HIV-1 molecular clone deleted of VPU
(HIVDΔVPU) and plasmid expressing VPU-tagged with the HA epitope
have been previously described (Arnaud et al., 2010; McNatt et al.,
2009; Neil et al., 2006, 2008). pCI (Promega) was used as an empty
plasmid control. pUCSBVST7, pUCSBVMT7 and pUCSBVLT7 (Varela
et al., 2013) encode the full-length antigenomic S, M and L SBV
segments and were used to rescue SBV. TVT7R-SBVM-ren [-] encodes
a chimeric antigenomic SBV M segment where the M protein coding
region has been replaced by the Renilla luciferase gene. pTM1-SBV-N
and pTM1-SBV-L express the N and L proteins of SBV under the
control of the T7 promoter. pUCAKAVST7, pUCAKAVMT7 and
pUCAKAVLT7 encode the full-length antigenomic S, M and L AKAV
segments and were used to rescue AKAV by reverse genetics. Plasmids
were synthesized commercially and derived from complete AKAV
sequences available in GenBank (AB190458.1; AB100604.1;
AB000851.1). The sequences of the chimeric BTS2 genes are presented
as Supplemental information (Supplemental experimental procedures
1).
2.5. Concentration of virions
800–900 µl of infected supernatants were filtered, layered over
600 µl of cold 20% sucrose and virions were pelleted by centrifugation
at 25,000g for 100 min. Virions were then resuspended in 20 µl of 1 x
Laemmli buffer and heated at 95⁰C for 5 min followed by western blot
analysis.
2.6. Recovery of intracellular infectious SBV
Cells were infected at a MOI of 0.001 in triplicate. 48 h post-
infection supernatants were removed, cells washed with PBS with 2%
FBS and scraped using 500 µl of PBS supplemented with 2% FBS
followed by two cycles of freeze-thawing. Cell debris were then pelleted
and supernatants titrated by limiting dilution. The experiment was
performed three times independently.
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2.7. Protease stripping assay
293-hBST2 or control cells were infected with SBV (MOI of 0.001)
and 48 h post-infection supernatants were then collected, filtered and
virions pelleted as described above. The remaining cells were washed
twice with PBS before they were treated with either PBS, dilution buffer
(10 mM Tris [pH 8.0], 1 mM CaCl2, and 150 mM NaCl) or subtilisin A
(10 µg/ml dilution buffer) for 45 min at 37⁰C. The reaction was then
stopped by the addition of 10% FBS DMEM and 5 mM of PMSF and
supernatants were collected, filtered and virions pelleted as described
above. Cells were lysed using 1X Laemmli buffer. Samples were
analyzed by western blotting.
2.8. RNA interference
Lentiviral vectors were used to stably express hairpin RNAs against
hBST2 or GFP as a control to knockdown BST-2 expression in human
primary fibroblasts (Blondeau et al., 2013; Wilson et al., 2007). The
relative levels of hBST-2 transcripts were estimated by quantitative RT-
PCR sung the Brilliant III Ultra Fast qRT-PCR master mix and the
following primers and probe: hBST-FW TGATGGCCCTAATGGCTTCC;
hBST-RW AGACCTGGTTTTCTCTTCTCAGTCG; and hBST FAM-
CCTCAAGCTCCTCCACTTTCTTTTGTCCTT-BBQ. Actin was used as a
normalizing control. Reactions were cycled on a Stratagene Mx3005
qPCR System (Agilent Technologies) and data was analyzed with the
Mx3000P software. The data is expressed as the Log10 relative
reduction in expression compared to the cell line expressing a GFP
shRNA.
2.9. Quantification of viral mRNA
293-hBST2 and control cells were infected (MOI of 0.001) for 1 h at
4⁰C to synchronize infection followed by 1.5 h at 37⁰C. Cells were then
cultured for 1, 2 and 5 h when total RNA was extracted using the
Fig. 1. Human BST-2 hampers SBV replication. (A) Western blot analysis of SBV virions generated by rescue of SBV by reverse genetics in parallel to transient expression of
hBST2 or an empty plasmid as a control. Virions were identified using antibodies towards the nucleocapsid (N) protein. (B) Representative experiment showing SBV growth kinetics in
HEK 293T transiently transfected with 500 ng of an expression plasmid of hBST2 or an empty plasmid as a control before infection with SBV (top panel). (C) Western blot analysis (anti
HA tag) confirming hBST2 expression in each of the three replicate wells (bottom panel). (D) 293-hBST2 and 293-control cells were analyzed by confocal microscopy using antibodies
against the HA tag to detect hBST2 (red). No unspecific background staining was visible in control cells (not shown). (E) Western blot analysis of HIV-1 virions (capsid-p24) generated
by transfection of 293-hBST2 and control cells with an HIV-1 molecular clone lacking the VPU gene. (F) SBV growth kinetics in 293-hBST2 cells. Results are expressed as the log10
TCID50 per ml of the average of three independent experiments, using two independent virus preparations (paired t-test). (G) Representative experiment showing SBV growth kinetics in
293-hBST2 and control cells transiently transfected with 500 ng of an expression plasmid of HIV-1 VPU or an empty plasmid (pCI) before infection with SBV (MOI 0.001). All the
experiments displayed in this figure were done in triplicate and repeated at least three times. *P ≤ 0.05; ** P ≤ 0.01; ***P ≤ 0.001; ****P ≤ 0.0001.
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RNAeasy mini kit (Qiagen). Viral RNA was reverse transcribed using a
SBV specific primer (5′ TTCGGCCCCAGGTGCAAATC 3′) with
AccuScript HF reverse transcriptase following manufacturer's instruc-
tions. cDNA was used for qRT-PCR using the Brilliant III Ultra Fast
QPCR master mix as indicated by the manufacturer. The following
primers and probe were used: SBV-S-FW (TCAGATTGTCATGCCC
CTTGC); SBV-S-RW (TTCGGC CCCAGG TGCAAATC); and SBV-S-
FAM (TTAAGGGATGCACCTGGGCCGATGGC). Reactions were cycled
on a Stratagene Mx3005 qPCR System (Agilent Technologies) and data
was analyzed with the Mx3000P software.
2.10. Mini replicon assays
SBV mini replicon assays were performed in parallel in 293-hBST2
and 293T-control cells. Cells were transfected with 300 ng of TVT7R-
SBVM-ren [-], 300 ng of pTM1-SBV-N, 150 ng of pTM1-SBV-L and
Fig. 2. hBST2 does not induce the accumulation of SBV within the cytoplasm or cell membrane of infected cells. (A) 293-hBST2 and control cells were infected at a MOI
of 0.001 and supernatants collected after 48 h. Cells were then incubated with PBS, buffer or subtilisin A (in duplicate) and supernatants were collected, filtered and virions pelleted by
centrifugation. The right panel shows SBV virions recovered from supernatants before treatment to show hBST2 restriction of SBV which was complete in this case. The experiment was
repeated independently three times. (B) 293-hBST2 and 293-control cells were infected at a MOI of 0.001 and 48 h post infection virions were released from the cytoplasm by freeze and
thaw cycles. Infectious viral titers were determined by limiting dilution. The graph shows the average and standard deviation of three independent experiments. (C) 293-hBST2 and 293-
control cells were infected at a MOI of 0.001 and 48 h post infection cells were lysed and analyzed by quantitative western blotting using a SBV N antibody. γ-tubulin was used to
equilibrate protein loading. Results are presented relative to control cells. The graph shows the average and standard deviation of three independent experiments (t-test p < 0.0001). (D)
293-hBST2 and 293-control cells were infected with SBV at a MOI of 0.001. 5 h post infection the culture media was supplemented with 1, 5 and 10 µM of lactacystin. Cell lysates were
collected 14 h later and analyzed by western blotting as described in C. Results show the average of two independent experiments performed in triplicates and are presented relative to
control cells (unpaired t-test). (E) Quantification of viral mRNA (S segment) by qRT-PCR in 293-hBST2 cells and control cells. Values represent the average of three independent
experiments and are presented relative to control cells (unpaired t-test). (F) SBV mini replicon assay in 293-hBST2 cells and 293-control cells. Values represent the average of four
independent experiments and are presented relative to control cells (100%; unpaired t-test). *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001; ****P ≤ 0.0001.
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250 ng of pCMV-T7 plasmids using Transit-LT1 (Mirus Bio LLC)
following the manufacturer's instructions. 24 h later, luciferase activity
was measured using the Dual-Luciferase® Reporter Assays System
(Promega). The experiment was performed four times, each time in
triplicate.
2.11. Statistical analysis
Statistical analysis was performed using GraphPad Prism. All
graphs show the averages and standard deviations.
3. Results
3.1. Human BST-2 restricts SBV replication
Initially, in order to test the sensitivity of orthobunyaviruses to
BST-2, we rescued SBV by plasmid transfection of BSR-T7/5 cells
in the presence or absence of hBST2. Five days post-transfection,
supernatants were collected, virus concentrated by centrifugation
and pellets analyzed by western blotting (Fig. 1A). We found a
reduction in the amount of SBV nucleocapsid protein (SBV N) in
the supernatants of transfected cells suggesting less efficient rescue
of SBV in the presence of hBST2. To confirm these results, HEK
293T cells were transiently transfected with a plasmid expressing
the hBST2 gene or an empty plasmid as a control and 14 h post-
transfection cells were infected with SBV at a low multiplicity of
infection (MOI 0.001). Virus replication kinetics was monitored for
72 h. We found decreased SBV infectious titers in samples derived
from cells transfected with hBST2 compared to control cells
(Fig. 1B-C). We then developed HEK 293T cells stably expressing
hBST2 (termed 293-hBST2) by transduction with retroviral vectors
carrying hBST2 tagged with the HA epitope or an empty retroviral
vector (termed 293-control) as a negative control. As shown in
Fig. 1D, all cells expressed hBST2 and, as expected, this cell line
was capable of restricting the release of HIV-1 lacking the accessory
protein Vpu, a known BST-2 antagonist (Neil et al., 2008) (Fig. 1E).
We then compared the SBV replication kinetics in 293-hBST2 and
293-control (Fig. 1F). We found a 10-fold reduction in the titers of
SBV produced in 293-hBST2 cells compared to those obtained in
293-control. We obtained the same results using another indepen-
dently established HEK 293T cell line stably expressing huBST2
(not shown). Importantly, the restriction of SBV in 293-hBST2 cells
could be partially overcome by transient transfection of a plasmid
expressing HIV-1 Vpu, a known BST2 antagonist (Fig. 1G).
3.2. hBST2 does not affect the early stages of the SBV replication cycle
nor the intracellular localization of its nucleocapsid protein
We infected 293-hBST2 and 293-control cells with SBV to address
whether hBST2 impacts the early stages of the SBV replication cycle.
We then counted the number of infected cells at 8 and 12 h post-
infection by immunofluorescence using an antiserum against the SBV
N protein. We reasoned that if hBST2 blocks SBV entry, we would find
a reduction in the number of virus positive cells early after infection.
We found no difference in the number of SBV positive cells between
293-hBST2 and control cells indicating that hBST2 does not impact
SBV entry (Fig. S1A). In addition, we found no difference in the
intracellular distribution of SBV nucleocapsid (N) protein between
293-hBST2 and 293-control infected cells by confocal microscopy (Fig.
S1B).
There was no evidence of accumulation of SBV N at the cell
membrane of 293-hBST2 infected cells by confocal microscopy, a
typical phenotype observed as a result of BST-2 restriction (Blondeau
et al., 2013; Neil et al., 2008; Wang et al., 2014). In order to confirm
these data, we performed a protein stripping assay. If hBST2 causes
protein tethering on the surface of virus-infected cells we would expect
to recover more virions from hBST2-expressing cells than control cells
after protease treatment. 293-hBST2 and control cells were infected
with SBV and 48 h post-infection virions were stripped from the cell
surface by treatment with the protease subtilisin-A. Controls included
treatment with PBS and the buffer used for subtilisin-A reconstitution.
Interestingly, more virions were recovered from control cells than from
hBST2- expressing cells (Fig. 2A).
We then quantified and compared the amount of intracellular
infectious virus in 293-hBST2 and 293-control cells. Cells were
infected with SBV and after 48 h supernatants were removed and
cells lysed by freeze-thawing. Infectious titers of cell-associated
SBV particles were measured by endpoint dilution analysis. We
found the titers of cell-associated SBV preparations derived from
293-hBST2 lower compared to control cells in each of three
independent experiments, although this difference did not reach
statistical significance (Fig. 2B). Hence, we also assessed the
relative amount of intracellular SBV N in lysates of infected cells
by quantitative western blotting. We found a significant reduction
in the amount of SBV N in lysates derived from 293-hBST2
compared to control cells (Fig. 2C). To determine if hBST2 induces
the degradation of SBV proteins, we repeated the experiments
above in the presence or absence of the proteasome inhibitor
lactacystin. Lactacystin treatment could not rescue the decrease
of SBV N in cell lysates indicating that hBST2 does not induced the
degradation of SBV virions via the proteasome (Fig. 2D).
Taken together these results indicate that both the steady-state
levels of cell-associated SBV proteins and virions released in the
supernatants are reduced in the presence of hBST2. Therefore, we
investigated if hBST2 has an impact in the activity of SBV
polymerase and/or the formation of the ribonucleoprotein complex
(RNP). To this end, 293-hBST2 and 293-control were infected and
viral RNA quantified at 1, 2 and 5 h post-infection by qRT-PCR. We
found no statistically significant differences in the amount of viral
RNAs in cells expressing hBST2 compared to control cells, indicat-
ing that hBST2 has no impact on SBV polymerase activity (paired t-
test) (Fig. 2E). In addition, we used a mini replicon assay for SBV in
order to assess viral polymerase activity in either 293-hBST2 and
293-control cells as previously described (Dong et al., 2013). We
found no differences in luciferase activity between cells expressing
hBST2 and control cells indicating that hBST2 does not impact SBV
polymerase activity or the formation of the RNP complex (Fig. 2F).
3.3. hBST2 restricts SBV replication by reducing the amount of
envelope glycoproteins in viral particles
Next, we compared the infectivity of SBV virions released into
the supernatant of cells expressing hBST2 or control cells. 293-
hBST2 and 293-control cells were infected and 48 h later super-
natants collected, filtered and the number of viral genomes quan-
tified by qRT-PCR. These supernatants were then used to infect
CPT-Tert cells (sheep choroid plexus cells) using 2.5 × 105 of SBV
genome equivalents. 8 h post-infection CPT-Tert cells were fixed
and analyzed by confocal microscopy using an antibody against
SBV N. The number of SBV positive cells was counted and
compared between groups. We found a significant decrease in the
number of SBV positive cells in CPT-Tert cells infected with 2.5 ×
105 genome equivalents of SBV generated in 293-hBST2 compared
to those infected with the equivalent amount of genomes generated
in 293-control cells (Fig. 3A).
Next, we assessed the relative amount of the Gc SBV glycopro-
tein present in SBV virions generated in 293-hBST2 and 293-
control cells. Virions in supernatants collected from infected cells
were pelleted and analyzed by western blot analysis. SBV N and Gc
were quantified and the Gc/N ratio calculated (Fig. 3B). We found a
significant decrease in the Gc/N ratio in SBV virions produced in
293-hBST2 suggesting that viral envelope protein incorporation is
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hampered by hBST2. In order to understand whether the reduced
amount of Gc glycoprotein in released virions was the result of a
reduced production of Gc in cells stably expressing hBST2 or rather
due to the reduced incorporation of Gc into nascent virions, we
quantified the amount of Gc in total cells lysates of 293-hBST2 and
293-control cells infected with SBV. To capture the kinetics of Gc
expression. To capture the kinetics of Gc expression, we collected
lysates early post infection starting from 12 h, which was the
earliest time point in which we could detect viral protein expres-
sion by western blotting (Fig. 3C). We found statistically significant
reduced quantities of Gc glycoprotein in hBST2 cells relative to
control cells at all times post infection except at 12 h. At the same
time, we quantified the quantities of N and we found that these
were also reduced in SBV-infected 293-hBST2 relative to 293-
control cells, but the differences reached statistical significance
only at 16 h post infection. We also quantified the relative effect of
hBST2 on Gc and N expression by estimating the area under the
curve (AUC) between 12 and 22 h post infection in 293-control and
293-hBST32. We found a bigger difference in the AUC between
293-hBST2 and 293-control cells for Gc than for N, supporting the
idea that hBST2 targets Gc production more effectively.
3.4. BST-2 orthologues restrict orthobunyaviruses in a host-
dependent manner
We then monitored the replication kinetics of other ruminant
orthobunyaviruses including AKAV and SATV in 293-hBST2 and
293-control cells. We found that hBST2 restricts the replication of
AKAV and SATV (approximately 100 fold at 48 hpi), similarly to what
we showed for SBV (Fig. 4A). On the other hand, hBST2 is unable to
restrict the replication of OROV and LACV, both human orthobunya-
virus (Fig. 4A) nor Cache Valley virus (CVV) an orthobunyavirus known
to infect both ruminants and humans.
Given that BST-2 might have played a fundamental role in the
transmission of pandemic HIV-1 M group from chimpanzees to
humans (Sauter et al., 2009) and, as shown above, orthobunyaviruses
with ruminant tropism are restricted by hBST2 while orthobunya-
viruses with human tropism are not, we asked the question as to
whether BST-2 restriction correlates with orthobunyavirus host range.
To this end, we developed HEK 293T cell lines stably expressing the
ovine orthologues of BST-2 (oBST2A and oBST2B) and assessed the
replication kinetics of the bunyaviruses used above. We found that the
replication of orthobunyaviruses with only ruminant tropism (SBV,
Fig. 3. SBV virions produced in 293-hBST2 are less infectious due to reduced levels of envelope glycoprotein. (A) 293-hBST2 or 293-control cells were infected with
SBV (MOI 0.001) and cultured for 48 h when supernatants were collected, filtered through a 0.45 µm filter and the number of SBV genomes quantified by qRT-PCR. CPT-Tert cells were
then infected with 2.5 × 105 SBV genome equivalents of these supernatants for one hours at 4 °C to synchronize infection followed by 1.5 h at 37 °C. 8 h post infection cells were fixed
and stained by immunofluorescence using an antiserum against SBV N. The number of SBV infected cells was counted (10 fields of view per condition) and compared between groups.
Three independent experiments were carried out using three independent viral preparations produced in 293-hBST2 and 293-control cells. Values represent the average of three
independent experiments and are presented relative to control cells (100%) (t-test p < 0.05). (B) SBV stocks were produced as described in A and virions pelleted through a 20% sucrose
cushion by centrifugation followed by quantitative western blot analysis. The graph displays the average of the Gc/N ratio of at least five independent experiments (t-test p < 0.05). (C)
293-hBST2 or 293-control cells were infected with SBV (MOI 0.001) and total cell lysates were collected at the indicated times post infection and analyzed by quantitative western
blotting against SBV N and Gc proteins. The data is expressed relative to the expression of control cells at 22 h post-infection. The graph displays the average of three independent
experiments (two-way ANOVA). (D) The area under the curve (AUC) for each of the individual experiments depicted in (C) was estimated and compared between groups (t-test). *P ≤
0.05; **P ≤ 0.01; ***P ≤ 0.001; ****P ≤ 0.0001.
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AKAV and SATV) was not impaired by oBST2A and oBST2B (Fig. 4B).
However, the replication of human-tropic OROV and LACV was
restricted by the ovine BST2 orthologues (Fig. 4B). As expected the
ovine orthologues could not restrict the replication of CVV. The
patterns of expression of the 293-oBST2A and 293-oBST2B cell lines
are shown in Fig. 4C. Altogether, these data suggest that there is a
correlation between the capacity of BST2 to restrict orthobunyavirus
replication and their host range.
To corroborate our results in a more relevant in vitro model, we
assessed the replication kinetics of some of the viruses described above
in primary sheep and human fibroblasts. We found species-specific
restriction of virus replication: all ruminant viruses (AKAV, SATV and
SBV) replicated to higher titers in sheep primary fibroblasts compared
to human fibroblasts, while OROV replicated to higher titers in human
fibroblasts compared to sheep fibroblast (Fig. 4C). Moreover, the
replication of SBV in human fibroblasts in general increased when
cells were transduced to stably express shRNAs against hBST2
(Fig. 4E). The levels of BST-2 knockdown are shown in Fig. 4F.
We then examined the ability of the human and ovine BST-2
orthologues to modulate the incorporation of envelope glycoprotein
into SBV and OROV virions. SBV and OROV stocks were produced in
293-hBST2, 293T-oBST2A, 293T-oBST2B or 293-control cells. Virions
in the supernatants were pelleted followed by western blot analysis.
SBV and OROV N and Gc were quantified and the Gc/N ratio calculated
(Fig. 5). As expected, we only found a reduced Gc/N ratio for SBV when
produced in hBST2 expressing cells but not when produced in oBST2A
and oBST2B cells (p = 0.0147). Conversely, we found a reduced Gc/N
ratio for OROV only when stocks were produced in oBST2B cells, the
only cell line able to restrict OROV replication (p < 0.05). We observed
a substantial difference in the Gn/N ratio between SBV and OROV,
however we attribute this difference to the differences in sensitivities of
each of the antibodies used against each viral protein.
4. Discussion
This is the first study identifying a host determinant of species
susceptibility to bunyavirus infection. We showed that orthologues of
BST-2, a cellular restriction factor with a broad antiviral activity
against enveloped viruses, restrict orthobunyavirus replication in a
host-specific manner. We found a correlation between the ability of
orthobunyaviruses to replicate in the presence of different BST-2
orthologues in vitro and the range of their susceptible hosts in natural
infections. In stable cell lines expressing different BST-2 orthologues,
OROV and LACV replication was restricted by sheep BST-2 but not by
human BST-2. On the other hand, viruses with ruminant tropism, such
as SBV, SATV and AKAV, were restricted by human BST-2 but not by
the ruminant orthologues. In addition, CVV, a virus of both humans
and ruminants, was not restricted by either orthologue. We found
delayed replication of the human virus OROV in primary sheep
fibroblast compared to primary human fibroblasts while the converse
was observed with the ruminant orthobunyaviruses SBV, SATV and
AKAV. Moreover, knock down of human BST-2 by small hairpin RNA
facilitated replication of SBV in primary human fibroblasts.
It is important to stress that orthobunyaviruses encode a non-
structural protein (NSs) that inhibits global cellular transcription and
therefore the activation of ISGs in general (Elliott, 2014). Hence, it may
be counterintuitive to expect that individual ISGs may contribute to
determine the host range of orthobunyaviruses considering that these
viruses hamper the host antiviral responses by blocking expression of
all ISGs. However, some restriction factors such as BST-2 are con-
stitutively expressed in some cell types in addition to being expressed
in response to IFN production. These factors are often referred to as
part of the “intrinsic” immune response of the host as they are available
in the cell even before pathogens are sensed and the IFN response is
initiated (Yan and Chen, 2012). Here, we show that BST-2 restricts
orthobunyavirus replication in a species-specific manner. In vitro,
orthobunyaviruses are able to infect a variety of cell lines of different
species. This indicates that the host range of these viruses does not
totally depend on receptor availability or other factors required for viral
replication. For example, SBV antibodies have been detected in deer,
elks, buffalos, alpacas and dogs among others (Lievaart-Peterson et al.,
2015) but so far disease has only been documented in ruminants in the
form of abortions and congenital malformations. AKAV has been
detected in camels, horses, buffalos and dogs but it is only pathogenic
Fig. 4. Differential restriction of orthobunuyaviruses by BST-2. SBV, AKAV, SATV, CVV, OROV and LACV growth kinetics in 293-hBST2 (A) and in 293-oBST2A and 293-
oBST2B cells (B). Cells were infected at a MOI of 0.001 and virus growth monitored for 48 h. The graphs represent the average of three independent experiments using two independent
virus preparations. Data was analyzed using a 2-way ANOVA. (C) 293-oBST2A and 293-oBST2B cells were analyzed by confocal microscopy using antibodies against the HA tag to detect
BST2 (green) to confirm expression. (D) Differential growth of orthobunuyaviruses in sheep and human primary fibroblasts. Cells were infected with the indicated viruses at a MOI of
0.01 and virus replication monitored for 48 h. Data was analyzed using a 2-way ANOVA. (E) Human primary fibroblasts were transduced with lentivirus to stably express three shRNA
against hBST2 (shRNAi, shRNAii and shRNAiii) or GFP as a control. Cells were infected with SBV at a MOI of 0.01 and virus titers assessed at 24 and 48 h post-infection. The graph
represents the average and standard deviation of four independent experiments. Data was analyzed using a 2-way ANOVA. (F) Relative quantification of BST-2 transcripts in human
primary fibroblasts stably expressing shRNAs against hBST-2 or GFP that was used as calibrator. *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001; ****P ≤ 0.0001.
Fig. 5. BST-2 restricts bunyavirus replication in a host specific manner by modulating the incorporation of envelope glycoprotein into virions. SBV (A) and OROV (B) stocks were
produced in the indicated BST2-expressing cells and virions pelleted by centrifugation followed by quantitative western blot analysis. The graph displays the average of the Gc/N ratio.
The data of the Gc/N ratio of SBV in 293-hBST2 of Fig. 4B has been included here for comparative purposes. Data was analyzed using a 1-way repeated measures ANOVA followed by
Dunnett's multiple comparison test. *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001; ****P ≤ 0.0001.
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in domestic ruminants (Kirkland, 2015). OROV causes febrile illness in
humans but it has also been isolated from primates and sloths (Bastos
Mde et al., 2012) while LACV causes encephalitis in humans but no
disease presents in chipmunks or squirrels which are also hosts (Beaty
and Calisher, 1991; Grimstad, 1988). We found that human BST-2 was
unable to restrict replication of OROV and LACV while the ovine
orthologues did not restrict the growth of the ruminant viruses SBV,
AKAV and SATV. Interestingly, neither the human nor the ruminant
BST-2 impaired the replication of CVV which has been associated with
abortions and congenital malformations in ruminants as well as
encephalitis in humans (Chung et al., 1990; Sexton et al., 1997).
These results are in accordance with a previous report which showed
that human BST-2 does not restrict the replication of Rift Valley Fever
virus, a phlebovirus responsible of congenital abnormalities in rumi-
nants as well as the cause of febrile illness in humans (Radoshitzky
et al., 2010).
Under our experimental design we showed that BST-2 does not
completely abolish viral replication, in line with the activity of this
protein against other enveloped viruses and thus BST-2 proteins of
different species likely restrict orthobunyaviruses with different effi-
ciency. However, the role of BST-2 in influencing orthobunyavirus host
range will likely derive from a variety of factors including its sites and
timing of expression and its efficiency of restriction of a given virus.
Ultimately many other factors, including the timing and efficiency of
total cellular protein shut-down induced by viral NSs will determine
orthobunyaviruses host range.
BST-2 is a versatile molecule that is not only able to restrict
replication of a variety of enveloped viruses but it is also implicated
in innate sensing, signaling and structural organization of the cell
(Sauter, 2014). The most common mechanism of viral restriction by
BST-2 described so far involves the physical attachment of virions to
the cell membrane of infected cells (Perez-Caballero et al., 2009).
However, we previously showed that the ovine orthologue oBST2B
restricts sheep retroviruses by reducing the incorporation of envelope
glycoprotein into nascent viral particles (Murphy et al., 2014). Here we
found that hBST2 restricts SBV replication by reducing the incorpora-
tion of the Gc glycoprotein into virions.
The mechanisms by which BST-2 targets orthobunyavirus glyco-
proteins are not known. However, it does not seem to be the result of a
general disruption of viral protein synthesis or turnover by BST-2 given
that the same orthologue expressed in the same cell line has a different
impact on replication of different orthobunyaviruses. In addition,
restriction is not impacted by the addition of inhibitors of the
proteasome thus discarding the possibility that BST-2 can induce the
degradation of viral proteins. One of the ovine paralogues (oBST2B)
lacks a predicted glycosylation sites and the carboxy-terminal GPI
anchor which results in a protein that is retained within the Golgi
apparatus. Bunyaviruses are thought to assemble at membranes of the
Golgi apparatus that have been modified by the insertion of the viral
glycoproteins. Newly formed viral RNPs locate beneath the modified
membranes. It is believed that the interaction between the RNPs and
the cytoplasmic tail of either or both the viral glycoproteins triggers
budding (Overby et al., 2007; Shi et al., 2007). Thus, crosstalk between
orthobunyavirus glycoproteins and BST-2 orthologues may occur in
this cellular compartment. However, we found no SBV Gc and hBST2
colocalization in infected cells or expressing SBV Gc by transient
transfection indicating that the mechanism of action of hBST2 might
be either indirect or involve interaction with another viral protein (i.e.
Gn). On the other hand, we cannot assume that glycoproteins from
different orthobunyaviruses are translated and traffic in the cytoplasm
in exactly the same way. Hence, the species-specificity of BST-2
restriction could be related to differential translation and recruitment
of viral proteins for budding.
Emerging infectious diseases pose a threat to human and animal
populations. Viral emergence is a multifactorial event where ecological,
genetic, immunological and evolutionary processes play a key role in
determining its outcome. In general, little is known about the adaptive
changes that viruses require to cross the species barrier and emerge
into new species (Holmes and Drummond, 2007). Until now, scarce
information existed on the host genetic factors that determine ortho-
bunyavirus host range and what rules the emergence of these patho-
gens. This study provides for the first time clear clues on one of the host
genetic barriers that these viruses face to establish themselves in a new
host species.
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